About Entact Bio
Entact Bio is a company based in Watertown (United States) founded in 2022 by Sara Buhrlage, Ueli Nachbur, Jarrod Marto, Sylvie Urbe, and Michael Clague. Entact Bio has raised $130.9 million across 3 funding rounds from investors including Citadel, Janus Henderson Investors and Abingworth. Entact Bio offers products and services including ENTACs and Encompass Platform. Entact Bio operates in a competitive market with competitors including Nimbus Therapeutics, Cradle, EvolutionaryScale, Evozyne and Profluent Bio, among others.
- Headquarter Watertown, United States
- Founders Sara Buhrlage, Ueli Nachbur, Jarrod Marto, Sylvie Urbe, Michael Clague
- SectorsHealthcare
- Email••••••••
- Website entactbio.com
- Social LinkedIn X
- Total Equity Funding$130.9M (USD)
in 3 rounds
- Latest Funding Round$10M (USD), Series A
Jan 2026
- InvestorsCitadel
& 9 more
Products & Services of Entact Bio
Entact Bio offers a comprehensive portfolio of products and services, including ENTACs and Encompass Platform.
Bifunctional small molecules that enhance protein function for disease treatment.
End-to-end system for identifying and optimizing protein enhancement targets.
Funding Insights of Entact Bio
Entact Bio has successfully raised a total of $130.9M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $10 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $130.9M
- Total Rounds 3
- Last Round Series A — $10M
- First Round $81M
(Dec 2022)
- Investors Count 10
All 3 funding rounds of Entact Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
10 investors in total: 10 institutional.
Investors in Entact Bio
Entact Bio has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Citadel, Janus Henderson Investors and Abingworth.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare companies are funded by Qiming, a venture capital firm. | – | qimingvcusa.com | Cambridge, United States | |
A life sciences investment firm focused on novel therapeutics is operated. | 2011 | venbio.com | San Francisco, United States | |
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Private equity fund focused on the biotechnology sector | – | logoscapital.com | San Francisco, United States | |
- | – | 4biocapital.com | - | |
- | – | arkinholdings.com | - | |
Early-stage medical companies are funded by this venture capital firm. | – | brandoncapital.vc | Melbourne, Australia | |
Long, short, event-driven, and multiple strategies are employed by Citadel. | 1990 | citadel.com | Chicago, United States | |
Disease detection research is conducted by the laboratory. | 1915 | wehi.edu.au | United States |
Investor details for Entact Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Entact Bio
14 people are tracked at Entact Bio (13 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Sara Buhrlage | Founder | Leadership |
Ueli Nachbur | Founder | Leadership |
Jarrod Marto | Founder | Leadership |
Sylvie Urbe | Founder | Leadership |
Michael Clague | Founder | Leadership |
Bob Soh | Alternate Director | Leadership |
Victoria Richon | Chief Executive Officer | Leadership |
Owen Smith | Director | Leadership |
Elma Kadic | Director | Leadership |
Victor Serebrov | Director | Leadership |
Ruben Tommasi | Chief Scientific Officer | Leadership |
James Minissale | Associate Director | Leadership |
Michael Gutch | Chief Operating Officer | Leadership |
Simon Bushell | SVP, Molecular Discovery | Team |
Complete people profiles for Entact Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Entact Bio
3 dated milestones of Entact Bio across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Entact Bio is founded.
- Funding First funding round of $81.0M.
- Funding Latest funding round, Series A, of $10.0M.
Competitors of Entact Bio
Entact Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nimbus Therapeutics, Cradle, EvolutionaryScale, Evozyne and Profluent Bio, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| cradle.bio | 2021 | Delft, Netherlands | $102.71M | – | Chemoproteomics solutions are provided for protein design and development. | |
| evolutionaryscale.ai | 2023 | New York, United States | $142M | – | Provider of an AI models for protein design | |
| evozyne.com | 2020 | Chicago, United States | $144.37M | – | Developer of proteins using protein engineering technology | |
| profluent.bio | 2022 | Berkeley, United States | $44M | – | An AI-based protein design platform is provided for drug discovery. | |
| frontiermeds.com | 2018 | San Francisco, United States | $235.5M | 115 | Bioinformatics platform is developed for drug discovery and chemoproteomics. | |
| eikontx.com | 2019 | Hayward, United States | $1.16B | – | Protein dynamics are tracked and measured for drug discovery processes. |
Detailed competitors of Entact Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Entact Bio
The website of Entact Bio (entactbio.com) receives about 2.8K visits a month.
- Monthly visits2.8K
▲ 25.5% vs previous month
Latest news on Entact Bio
Complete news archive for Entact Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Entact Bio
10 companies that operate in the same segment as Entact Bio (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Entact Bio
Entact Bio was founded in 2022.
Entact Bio is headquartered in Watertown, United States.
Entact Bio is a funded company, having raised a total of $130.9M across 3 funding rounds to date. The company's 1st funding round was a Series A of $81M, raised on Dec 2022.
Entact Bio was founded in 2022 and is based in Watertown, United States. Operations focus on the biotechnology sector, where drugs are developed to improve the functions of beneficial proteins. A proprietary Encompass platform has been designed to produce enhancement-targeting chimeric (ENTAC) medicines. These medicines utilize deubiquitinating enzymes (DUBs) to regulate proteins, supporting targeted therapeutic advancements.
Entact Bio's top competitors include Nimbus Therapeutics, Cradle and Profluent Bio.
Entact Bio offers ENTACs and Encompass Platform.
Entact Bio has 10 investors. Key investors include Citadel, Janus Henderson Investors, Abingworth, WEHI, and Qiming.